This achievement is amply recognised by the wealth of impressive publications describing novel flow chemistry applications developed using Syrris reactors.
Today, scientists have access to hundreds of flow chemistry papers citing groundbreaking applications established on modular reactors from Syrris, including the Ley group’s Accelerating Spirocyclic Polyketide Synthesis using Flow Chemistry1. The group, based at the University of Cambridge, took advantage of the Asia reactor’s continuous analysis and work-up capabilities to synthesise the natural products Spirodienal A and Spirangien A. This pioneering process, using solids, liquids and gases, combines 16 stages of a 21-step synthesis into one flow chemistry sequence, demonstrating just how far flow techniques have advanced.
The pharmaceutical industry is also benefitting from continuous flow techniques, as well as microfluidic electrosynthesis, with publications including A three step continuous flow synthesis of the biaryl unit of the HIV protease inhibitor Atazanavir 2 and Preparative Microfluidic Electrosynthesis of Drug Metabolites3. Scientists worldwide can learn more about these and many other varied applications taking advantage of Syrris flow reactors – ranging from the early days of flow chemistry synthesis through to numerous present-day examples – by exploring the convenient reference guide at http://syrris.com/news/syrris-in-publications
1. Sean Newton, Catherine F. Carter, Colin M. Pearson, Leandro de C. Alves, Heiko Lange, Praew Thansandote, and Steven V. Ley (2014). Accelerating Spirocyclic Polyketide Synthesis using Flow Chemistry. Angew. Chem. Int. Ed. 53, 1-7.
2. Luciana Dalla-Vechia, Benedikt Reichart, Toma Glasnov, Leandro S. M. Miranda, C. Oliver Kappe and Rodrigo O. M. A. de Souza (2013). A three step continuous flow synthesis of the biaryl unit of the HIV protease inhibitor Atazanavir. Org. Biomol. Chem. 11, 6806-6813.
3. Romain Stalder and Gregory P. Roth (2013). Preparative Microfluidic Electrosynthesis of Drug Metabolites. ACS Med. Chem. Lett. 4 (11), 1119–1123.
___________________________________________________